Now in its 12th year, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care
Congratulations to the our 2024 cohort companies! After a competitive selection process with a five percent acceptance rate, 65 companies were chosen to participate in MTI’s flagship four-month Accelerator program. The BioTools Innovator program accepted the top 20 companies from a pool of more than 300 applicants from 33 countries and 35 U.S. states, while MedTech Innovator Asia Pacific also selected 20 companies for their 2024 cohort. These medical device, diagnostic, digital health, and biotools companies will access the seasoned expertise of strategics, manufacturers, healthcare providers, investors, and other industry stakeholders, along with unparalleled visibility. Cohort companies will compete for over $1M in non-dilutive funding throughout the 2024 program.